Real-Life Effectiveness of MP-AzeFlu (Dymista ® ) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale.

Pär StjärneDuc Tung NguyenHans Christian Kuhl

Published in: Pragmatic and observational research (2023)

MP-AzeFlu provides effective, rapid control of PER assessed by VAS in a real-world clinical setting in Sweden. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved sleep quality. MP-AzeFlu significantly improved the QoL of the patients and was well tolerated.

Keyphrases

sleep quality
allergic rhinitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
systematic review
prognostic factors
peritoneal dialysis